Virtus Biotech ETF BBP
102.40 USD +1.62 (+1.61%)
Nov 6, 2026, 1:00 PM EST
100.23 Day range 102.48
73.55 52-week range 110.05
- YTD
- +28.13%
- 1 year
- +38.01%
- Market cap
- 41.32M
- YTD return
- +28.13%
- 1-year return
- +38.01%
- Volume
- 9.82K
- Avg volume
- 12.36K
- Open
- 100.23
- Previous close
- 100.78
- Day's range
- 100.23 – 102.48
- 52-week range
- 73.55 – 110.05
5D -2.54 (-2.42%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 63.72
- 200-day average
- 60.18
About Virtus Biotech ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
News
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug 
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check 
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use 
Why Is ImmunityBio Stock Soaring On Friday? 
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug 
Why Is ImmunityBio Stock Gaining Tuesday? 
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion 
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch 
2 New Biotech ETFs Offer Unique Industry Focus
Your note
Sign in to keep a note on BBP — it syncs with the Stock Master app.